Beijing Aosaikang Pharmaceutical (002755.SZ): Research results of the innovative drug ASKB589 for first-line advanced gastric cancer will be released at ASCO GI in 2025.

Beijing Aosaikang Pharmaceutical (002755.SZ) announced that its subsidiary ASKGENE LIMITED presented the latest clinical research results of the investigational biologic drug ASKB589 (targeting CLDN18.2 monoclonal antibody) in combination with CAPOX (oxaliplatin and capecitabine) and PD-1 inhibitor in first-line treatment of advanced gastric/esophagogastric junction adenocarcinoma at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (2025 ASCO GI) on January 23, 2025. In this study, the combination of ASKB589 (targeting CLDN18.2 monoclonal antibody) with CAPOX (oxaliplatin and capecitabine) and PD-1 inhibitor as a first-line treatment regimen demonstrated significant tumor response, sustained survival benefits, good tolerability, and no additional safety risks were observed with the addition of PD-1 inhibitor. The study results support the initiation of a Phase III clinical trial of the ASKB589 triplet therapy targeting patients with advanced stage IV gastric/esophagogastric junction adenocarcinoma with high CLDN18.2 expression.